Literature DB >> 10546874

Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.

C D Pilcher, J J Eron, L Ngo, A Dusek, P Sista, J Gleavy, D Brooks, T Venetta, E DiMassimo, S Hopkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10546874     DOI： 10.1097/00002030-199910220-00024

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  3 in total

1.  Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Christopher Kollmann; Yongbiao Guan; Ting-Chao Chou; Bahige M Baroudy; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

3.  Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.

Authors:  Hiroshi Miyake; Yuji Iizawa; Masanori Baba
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.